{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:17:57Z","timestamp":1789676277243,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T00:00:00Z","timestamp":1410739200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1038\/aps.2014.76","type":"journal-article","created":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T08:58:44Z","timestamp":1410771524000},"page":"1342-1350","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Population pharmacokinetics modeling of oxcarbazepine to characterize drug interactions in Chinese children with epilepsy"],"prefix":"10.1038","volume":"35","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-nian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-he","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,15]]},"reference":[{"key":"BFaps201476_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.pediatrneurol.2005.05.011","volume":"33","author":"RS Northam","year":"2005","unstructured":"Northam RS, Hernandez AW, Litzinger MJ, Minecan DN, Glauser TA, Mangat S, et al. Oxcarbazepine in infants and young children with partial seizures. Pediatr Neurol 2005; 33: 337\u201344.","journal-title":"Pediatr Neurol"},{"key":"BFaps201476_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/S0009-9236(03)00124-3","volume":"74","author":"WM Sallas","year":"2003","unstructured":"Sallas WM, Milosavljev S, D'Souza J, Hossain M . Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther 2003; 74: 138\u201349.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps201476_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/WNF.0b013e31824150a5","volume":"35","author":"KJ Park","year":"2012","unstructured":"Park KJ, Kim JR, Joo EY, Seo DW, Hong SB, Ko JW, et al. Drug interaction and pharmacokinetic modeling of oxcarbazepine in korean patients with epilepsy. Clin Neuropharmacol 2012; 35: 40\u20134.","journal-title":"Clin Neuropharmacol"},{"key":"BFaps201476_CR4","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","volume":"42","author":"DTW May","year":"2003","unstructured":"May DTW, Korn-Merker E, Rambeck B . Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003; 42: 1023\u201342.","journal-title":"Clin Pharmacokinet"},{"key":"BFaps201476_CR5","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2165\/00044011-200424040-00001","volume":"24","author":"G Flesch","year":"2004","unstructured":"Flesch G . Overview of the clinical pharmacokinetics of oxcarbazepine. Clin Drug Investig 2004; 24: 185\u2013203.","journal-title":"Clin Drug Investig"},{"key":"BFaps201476_CR6","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos PN, Berry DJ, Bourgeois BF, Cloyd JC, Glauser TA, Johannessen SI, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239\u201376.","journal-title":"Epilepsia"},{"key":"BFaps201476_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/cp.1999.v66.103170001","volume":"66","author":"A Volosov","year":"1999","unstructured":"Volosov A, Xiaodong S, Perucca E, Yagen B, Sintov A, Bialer M . Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999; 66: 547\u201353.","journal-title":"Clin Pharmacol Ther"},{"key":"BFaps201476_CR8","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1124\/dmd.109.030593","volume":"39","author":"G Flesch","year":"2011","unstructured":"Flesch G, Czendlik C, Renard D, Lloyd P . Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine. Drug Metab Dispos 2011; 39: 1103\u201310.","journal-title":"Drug Metab Dispos"},{"key":"BFaps201476_CR9","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1111\/j.1528-1157.1994.tb05967.x","volume":"35 Suppl 5","author":"M Schmutz","year":"1994","unstructured":"Schmutz M, Brugger F, Gentsch C, McLean MJ, Olpe HR . Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 1994; 35 Suppl 5: S47\u201350.","journal-title":"Epilepsia"},{"key":"BFaps201476_CR10","first-page":"914","volume":"60","author":"MS Viola","year":"2000","unstructured":"Viola MS, Bercellini MA, Said\u00f3n P, Rubio MC . Pharmacokinetic variability of oxcarbazepine in epileptic patients. Medicina 2000; 60: 914\u20138.","journal-title":"Medicina"},{"key":"BFaps201476_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/01.ftd.0000155342.93489.fd","volume":"27","author":"JA Armijo","year":"2005","unstructured":"Armijo JA, Vega-Gil N, Shushtarian M, Adin J, Herranz JL . 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs. Ther Drug Monit 2005; 27: 199\u2013204.","journal-title":"Ther Drug Monit"},{"key":"BFaps201476_CR12","first-page":"525","volume":"52","author":"M Hossain","year":"1999","unstructured":"Hossain M, Sallas W, Gasparini M, D Souza J . Drug-drug interaction profile of oxcarbazepine in children and adults. Neurology 1999; 52: 525.","journal-title":"Neurology"},{"key":"BFaps201476_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/00007691-199904000-00007","volume":"21","author":"TW May","year":"1999","unstructured":"May TW, Rambeck B, Jurgens U . Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999; 21: 175\u201381.","journal-title":"Ther Drug Monit"},{"key":"BFaps201476_CR14","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2174\/157015910792246254","volume":"8","author":"SI Johannessen","year":"2010","unstructured":"Johannessen SI, Landmark CJ . Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol 2010; 8: 254\u201367.","journal-title":"Curr Neuropharmacol"},{"key":"BFaps201476_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1528-1157.1994.tb05938.x","volume":"35","author":"P Lloyd","year":"1994","unstructured":"Lloyd P, Flesch G, Dieterle W . Clinical pharmacology and pharmcokinetics of oxcarbazepine. Epilepsia 1994; 35: 10\u20133.","journal-title":"Epilepsia"},{"key":"BFaps201476_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3109\/00498258609043567","volume":"16","author":"H Schutz","year":"1986","unstructured":"Schutz H, Feldmann KF, Faigle JW, Kriemler HP, Winkler T . The metabolism of 14C-oxcarbazepine in man. Xenobiotica 1986; 16: 769\u201378.","journal-title":"Xenobiotica"},{"key":"BFaps201476_CR17","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1111\/j.1528-1167.2011.03318.x","volume":"53","author":"DW Kim","year":"2012","unstructured":"Kim DW, Gu N, Jang IJ, Chu K, Yu KS, Cho JY, et al. Efficacy, tolerability, and pharmacokinetics of oxcarbazepine oral loading in patients with epilepsy. Epilepsia 2012; 53: e9\u201312.","journal-title":"Epilepsia"},{"key":"BFaps201476_CR18","doi-asserted-by":"publisher","first-page":"524","DOI":"10.5414\/CPP40524","volume":"40","author":"G Flesch","year":"2002","unstructured":"Flesch G, Tudor D, Souppart C, D'Souza J, Hossain M . Oxcarbazepine final market image tablet formulation bioequivalence study after single administration and at steady state in healthy subjects. Int J Clin Pharmacol Ther 2002; 40: 524\u201332.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"BFaps201476_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.yebeh.2013.07.016","volume":"29","author":"I Wegner","year":"2013","unstructured":"Wegner I, Wilhelm AJ, Sander JW, Lindhout D . The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. Epilepsy Behav 2013; 29: 217\u201321.","journal-title":"Epilepsy Behav"},{"key":"BFaps201476_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2125.1993.tb00378.x","volume":"36","author":"A Tartara","year":"1993","unstructured":"Tartara A, Galimberti CA, Manni R, Morini R, Limido G, Gatti G, et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 1993; 36: 366\u20138.","journal-title":"Br J Clin Pharmacol"},{"key":"BFaps201476_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2165\/0003088-200847120-00002","volume":"47","author":"P Bring","year":"2008","unstructured":"Bring P, Ensom MH . Does oxcarbazepine warrant therapeutic drug monitoring? A critical review. Clin Pharmacokinet 2008; 47: 767\u201378.","journal-title":"Clin Pharmacokinet"},{"key":"BFaps201476_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1365-2125.1994.tb04234.x","volume":"37","author":"PJ McKee","year":"1994","unstructured":"McKee PJ, Blacklaw J, Forrest G, Gillham RA, Walker SM, Connelly D, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37: 27\u201332.","journal-title":"Br J Clin Pharmacol"},{"key":"BFaps201476_CR23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FTD.0b013e31825ee389","volume":"34","author":"LC Johannessen","year":"2012","unstructured":"Johannessen LC, Baftiu A, Tysse I, Valso B, Larsson PG, Rytter E, et al. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. Ther Drug Monit 2012; 34: 440\u20135.","journal-title":"Ther Drug Monit"},{"key":"BFaps201476_CR24","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1111\/j.1528-1167.2010.02771.x","volume":"51","author":"I Wegner","year":"2010","unstructured":"Wegner I, Edelbroek P, de Haan GJ, Lindhout D, Sander JW . Drug monitoring of lamotrigine and oxcarbazepine combination during pregnancy. Epilepsia 2010; 51: 2500\u20132.","journal-title":"Epilepsia"},{"key":"BFaps201476_CR25","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1111\/j.0013-9580.2003.06203.x","volume":"44","author":"SC Nallani","year":"2003","unstructured":"Nallani SC, Glauser TA, Hariparsad N, Setchell K, Buckley DJ, Buckley AR, et al. Dose-dependent induction of cytochrome P450 (CYP) 3A4 and activation of pregnane X receptor by topiramate. Epilepsia 2003; 44: 1521\u201328.","journal-title":"Epilepsia"},{"key":"BFaps201476_CR26","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/01.ftd.0000179847.37965.4e","volume":"27","author":"E Perucca","year":"2005","unstructured":"Perucca E . Pharmacokinetic variability of new antiepileptic drugs at different ages. Ther Drug Monit 2005; 27: 714\u20137.","journal-title":"Ther Drug Monit"},{"key":"BFaps201476_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF00194967","volume":"47","author":"MC Rouan","year":"1994","unstructured":"Rouan MC, Lecaillon JB, Godbillon J, Menard F, Darragon T, Meyer P, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994; 47: 161\u20137.","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps201476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201476","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps201476.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:32:00Z","timestamp":1684413120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps201476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,15]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["BFaps201476"],"URL":"https:\/\/doi.org\/10.1038\/aps.2014.76","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,15]]},"assertion":[{"value":"4 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}